VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
0.1416
+0.0001 (0.07%)
At close: Nov 6, 2026, 4:00 PM EST
0.1450
+0.0034 (2.40%)
After-hours: Nov 6, 2026, 7:59 PM EST
VivoSim Labs Revenue
VivoSim Labs had revenue of $18.00K in the quarter ending June 30, 2026, a decrease of -51.35%. This brings the company's total for the last twelve months to $112.00K, down -21.13% year-over-year. In the fiscal year ending March 31, 2026, VivoSim Labs had annual revenue of $131.00K, down -9.03%. That makes VivoSim Labs the 45,965th largest company in the world by revenue and 6,763rd in the United States.
Revenue (ttm)
$112.00K
Revenue Growth
-21.13%
P/S Ratio
21.33
Revenue / Employee
$7,467
Employees
15
Market Cap
2.35M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 131.00K | -13.00K | -9.03% |
| Mar 31, 2025 | 144.00K | 35.00K | 32.11% |
| Mar 31, 2024 | 109.00K | -261.00K | -70.54% |
| Mar 31, 2023 | 370.00K | -1.13M | -75.33% |
| Mar 31, 2022 | 1.50M | - | - |
| Mar 31, 2021 | - | - | - |
| Mar 31, 2020 | 2.20M | -895.00K | -28.96% |
| Mar 31, 2019 | 3.09M | -1.51M | -32.85% |
| Mar 31, 2018 | 4.60M | 373.00K | 8.82% |
| Mar 31, 2017 | 4.23M | 2.75M | 185.23% |
| Mar 31, 2016 | 1.48M | 912.00K | 159.72% |
| Mar 31, 2015 | 571.00K | 192.00K | 50.66% |
| Mar 31, 2014 | 379.00K | -818.00K | -68.34% |
| Dec 31, 2012 | 1.20M | 228.00K | 23.53% |
| Dec 31, 2011 | 969.00K | - | - |
| Jun 30, 2011 | - | - | - |
| Jun 30, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.62M |
| HCW Biologics | 6.72M |
| Curis | 4.31M |
| Onconetix | 645.82K |
| Silo Pharma | 54.08K |
VIVS News
- 3 days ago - VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test - GlobeNewsWire
- 16 days ago - VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling - GlobeNewsWire
- 4 weeks ago - VivoSim celebrates updated FDA regulations in non-animal testing methods - TheFly
- 4 weeks ago - VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods - GlobeNewsWire
- 7 weeks ago - VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs - GlobeNewsWire
- 2 months ago - VivoSim Labs to Add Rat Liver Model to NAMkind Platform - GlobeNewsWire
- 3 months ago - VivoSim regains compliance with Nasdaq - TheFly
- 3 months ago - VivoSim Provides Financial and Listing Compliance Update - GlobeNewsWire